Jacqueline Hanna, PharmD, MSPBA, CSP

On November 2018, the FDA approved Pfizer’s glasdegib (Daurismo) for the treatment of newly diagnosed acute myeloid leukemia (AML) in patients 75 years and older with comorbidities that prevent the use of intensive induction-dose chemotherapy.

Mergers and acquisitions among health care giants are causing massive disruption in specialty pharmacy.

The importance of improving the specialty pharmacy experience for patients newly diagnosed with a life-changing disease.

The potential for prescription drugs to cost more than $1 million for a treatment regimen creates a mixed bag of conundrums for the health care system.

Each member of the specialty pharmacy care team is an essential component in influencing and ensuring positive outcomes of therapy.

Specialty pharmacy can benefit from having definitive a center of excellence model that caters to respective therapies and disease states.

Specialty pharmacies and their patients now require technology systems that are more sophisticated in nature than the basic functions used in the past.

Involvement with the organizations and nonprofit foundations that focus on specialty disease states can help specialty pharmacists gain perspective on the patients they treat.